Nicotinamide adenine dinucleotide (NAD) is a coenzyme
central to metabolism
. Found in all living cell
s, NAD is called a dinucleotide because it consists of two nucleotide
s joined through their phosphate
groups. One nucleotide contains an adenine nucleobase
and the other nicotinamide
. NAD exists in two forms: an oxidized
form, abbreviated as NAD and NADH (H for hydrogen
, nicotinamide adenine dinucleotide is involved in redox
reactions, carrying electron
s from one reaction to another. The cofactor is, therefore, found in two forms in cells: NAD is an oxidizing agent
– it accepts electrons from other molecules and becomes reduced
. This reaction forms NADH, which can then be used as a reducing agent
to donate electrons. These electron transfer
reactions are the main function of NAD. However, it is also used in other cellular processes, most notably as a substrate
in adding or removing
to or from, respectively, proteins
, in posttranslational modification
s. Because of the importance of these functions, the enzymes involved in NAD metabolism are targets for drug discovery
In organisms, NAD can be synthesized from simple building-blocks (''de novo''
) from either tryptophan
or aspartic acid
, each a case of an amino acid
; alternatively, more complex components of the coenzymes are taken up from nutritive compounds such as niacin
; similar compounds are produced by reactions that break down the structure of NAD, providing a salvage pathway
that “recycles” them back into their respective active form.
Some NAD is converted into the coenzyme nicotinamide adenine dinucleotide phosphate
(NADP); its chemistry largely parallels that of NAD, though predominantly its role is as a cofactor in anabolic metabolism
The NAD chemical species
addition sign reflects the formal charge
on one of its nitrogen atoms; this species is actually a singly charged anion
— carrying a (negative) ionic charge of 1 — under conditions of physiological pH
. NADH, in contrast, is a doubly charged anion, because of its two bridging phosphate groups.
Physical and chemical properties
Nicotinamide adenine dinucleotide consists of two nucleoside
s joined by a pair of bridging phosphate groups. The nucleoside
s each contain a ribose
ring, one with adenine
attached to the first carbon atom (the 1'
position) (adenosine diphosphate ribose
) and the other with nicotinamide
at this position. The nicotinamide moiety
can be attached in two orientations to this anomer
ic carbon atom. Because of these two possible structures, the compound exists as two diastereomer
s. It is the β-nicotinamide diastereomer of NAD that is found in organisms. These nucleotides are joined together by a bridge of two phosphate
groups through the 5' carbons.
In metabolism, the compound accepts or donates electrons in redox reactions.
Such reactions (summarized in formula below) involve the removal of two hydrogen atoms from the reactant (R), in the form of a hydride ion
), and a proton
(H). The proton is released into solution, while the reductant RH is oxidized and NAD reduced to NADH by transfer of the hydride to the nicotinamide ring.
:RH + NAD → NADH + H + R;
From the hydride electron pair, one electron is transferred to the positively charged nitrogen of the nicotinamide ring of NAD, and the second hydrogen atom transferred to the C4 carbon atom opposite this nitrogen. The midpoint potential
of the NAD/NADH redox pair is −0.32 volt
s, which makes NADH a strong ''reducing'' agent.
The reaction is easily reversible, when NADH reduces another molecule and is re-oxidized to NAD. This means the coenzyme can continuously cycle between the NAD and NADH forms without being consumed.
In appearance, all forms of this coenzyme are white amorphous powders that are hygroscopic and highly water-soluble. The solids are stable if stored dry and in the dark. Solutions of NAD are colorless and stable for about a week at 4 °C and neutral pH, but decompose rapidly in acids or alkalis. Upon decomposition, they form products that are enzyme inhibitors.
Both NAD and NADH strongly absorb ultraviolet light because of the adenine. For example, peak absorption of NAD is at a wavelength of 259 nanometers (nm), with an extinction coefficient of 16,900 M−1cm−1. NADH also absorbs at higher wavelengths, with a second peak in UV absorption at 339 nm with an extinction coefficient of 6,220 M−1cm−1.] This difference in the ultraviolet absorption spectra between the oxidized and reduced forms of the coenzymes at higher wavelengths makes it simple to measure the conversion of one to another in enzyme assays – by measuring the amount of UV absorption at 340 nm using a spectrophotometer. [
NAD and NADH also differ in their fluorescence. NADH in solution has an emission peak at 340 nm and a fluorescence lifetime of 0.4 nanoseconds, while the oxidized form of the coenzyme does not fluoresce.] The properties of the fluorescence signal changes when NADH binds to proteins, so these changes can be used to measure dissociation constants, which are useful in the study of enzyme kinetics. [ These changes in fluorescence are also used to measure changes in the redox state of living cells, through fluorescence microscopy.]
Concentration and state in cells
In rat liver, the total amount of NAD and NADH is approximately 1 μmole per gram of wet weight, about 10 times the concentration of NADP and NADPH in the same cells. The actual concentration of NAD in cell cytosol is harder to measure, with recent estimates in animal cells ranging around 0.3 mM,
and approximately 1.0 to 2.0 mM in yeast. However, more than 80% of NADH fluorescence in mitochondria is from bound form, so the concentration in solution is much lower.
NAD concentrations are highest in the mitochondria, constituting 40% to 70% of the total cellular NAD. NAD in the cytosol is carried into the mitochondrion by a specific membrane transport protein, since the coenzyme cannot diffuse across membranes. The intracellular half-life of NAD+ was claimed to be between 1-2 hours by one review, whereas another review gave varying estimates based on compartment: intracellular 1-4 hours, cytoplasmic 2 hours, and mitochondrial 4-6 hours.
The balance between the oxidized and reduced forms of nicotinamide adenine dinucleotide is called the NAD/NADH ratio. This ratio is an important component of what is called the ''redox state'' of a cell, a measurement that reflects both the metabolic activities and the health of cells. The effects of the NAD/NADH ratio are complex, controlling the activity of several key enzymes, including glyceraldehyde 3-phosphate dehydrogenase and pyruvate dehydrogenase. In healthy mammalian tissues, estimates of the ratio between free NAD and NADH in the cytoplasm typically lie around 700:1; the ratio is thus favourable for oxidative reactions. The ratio of total NAD/NADH is much lower, with estimates ranging from 3–10 in mammals. In contrast, the NADP/NADPH ratio is normally about 0.005, so NADPH is the dominant form of this coenzyme. These different ratios are key to the different metabolic roles of NADH and NADPH.
NAD is synthesized through two metabolic pathways. It is produced either in a ''de novo'' pathway from amino acids or in salvage pathways by recycling preformed components such as nicotinamide back to NAD. Although most tissues synthesize NAD by the salvage pathway in mammals, much more ''de novo'' synthesis occurs in the liver from tryptophan, and in the kidney and macrophages from nicotinic acid.
''De novo'' production
Most organisms synthesize NAD from simple components.
[ The specific set of reactions differs among organisms, but a common feature is the generation of quinolinic acid (QA) from an amino acid—either tryptophan (Trp) in animals and some bacteria, or aspartic acid (Asp) in some bacteria and plants. The quinolinic acid is converted to nicotinic acid mononucleotide (NaMN) by transfer of a phosphoribose moiety. An adenylate moiety is then transferred to form nicotinic acid adenine dinucleotide (NaAD). Finally, the nicotinic acid moiety in NaAD is amidated to a nicotinamide (Nam) moiety, forming nicotinamide adenine dinucleotide.] [
In a further step, some NAD is converted into NADP by NAD kinase, which phosphorylates NAD. In most organisms, this enzyme uses ATP as the source of the phosphate group, although several bacteria such as ''Mycobacterium tuberculosis'' and a hyperthermophilic archaeon ''Pyrococcus horikoshii'', use inorganic polyphosphate as an alternative phosphoryl donor.
Despite the presence of the ''de novo'' pathway, the salvage reactions are essential in humans; a lack of niacin in the diet causes the vitamin deficiency disease pellagra. This high requirement for NAD results from the constant consumption of the coenzyme in reactions such as posttranslational modifications, since the cycling of NAD between oxidized and reduced forms in redox reactions does not change the overall levels of the coenzyme.
The major source of NAD in mammals is the salvage pathway which recycles the nicotinamide produced by enzymes utilizing NAD.] The first step, and the rate-limiting enzyme in the salvage pathway is nicotinamide phosphoribosyltransferase (NAMPT), which produces nicotinamide mononucleotide (NMN). NMN is the immediate precursor to NAD+ in the salvage pathway.
Besides assembling NAD ''de novo'' from simple amino acid precursors, cells also salvage preformed compounds containing a pyridine base. The three vitamin precursors used in these salvage metabolic pathways are nicotinic acid (NA), nicotinamide (Nam) and nicotinamide riboside (NR). [ These compounds can be taken up from the diet and are termed vitamin B or ''niacin''. However, these compounds are also produced within cells and by digestion of cellular NAD. Some of the enzymes involved in these salvage pathways appear to be concentrated in the cell nucleus, which may compensate for the high level of reactions that consume NAD in this organelle. There are some reports that mammalian cells can take up extracellular NAD from their surroundings, and both nicotinamide and nicotinamide riboside can be absorbed from the gut.
The salvage pathways used in microorganisms differ from those of mammals.] Some pathogens, such as the yeast ''Candida glabrata'' and the bacterium ''Haemophilus influenzae'' are NAD auxotrophs – they cannot synthesize NAD – but possess salvage pathways and thus are dependent on external sources of NAD or its precursors. Even more surprising is the intracellular pathogen ''Chlamydia trachomatis'', which lacks recognizable candidates for any genes involved in the biosynthesis or salvage of both NAD and NADP, and must acquire these coenzymes from its host.
Nicotinamide adenine dinucleotide has several essential roles in metabolism. It acts as a coenzyme in redox reactions, as a donor of ADP-ribose moieties in ADP-ribosylation reactions, as a precursor of the second messenger molecule cyclic ADP-ribose, as well as acting as a substrate for bacterial DNA ligases and a group of enzymes called sirtuins that use NAD to remove acetyl groups from proteins. In addition to these metabolic functions, NAD+ emerges as an adenine nucleotide that can be released from cells spontaneously and by regulated mechanisms,
and can therefore have important extracellular roles. [
Oxidoreductase binding of NAD
The main role of NAD in metabolism is the transfer of electrons from one molecule to another. Reactions of this type are catalyzed by a large group of enzymes called oxidoreductases. The correct names for these enzymes contain the names of both their substrates: for example NADH-ubiquinone oxidoreductase catalyzes the oxidation of NADH by coenzyme Q. However, these enzymes are also referred to as ''dehydrogenases'' or ''reductases'', with NADH-ubiquinone oxidoreductase commonly being called ''NADH dehydrogenase'' or sometimes ''coenzyme Q reductase''.
There are many different superfamilies of enzymes that bind NAD / NADH. One of the most common superfamilies include a structural motif known as the Rossmann fold.
The motif is named after Michael Rossmann who was the first scientist to notice how common this structure is within nucleotide-binding proteins.
An example of a NAD-binding bacterial enzyme involved in amino acid metabolism that does not have Rossmann fold is found in ''Pseudomonas syringae'' pv. tomato (; ).
When bound in the active site of an oxidoreductase, the nicotinamide ring of the coenzyme is positioned so that it can accept a hydride from the other substrate. Depending on the enzyme, the hydride donor is positioned either "above" or "below" the plane of the planar C4 carbon, as defined in the figure. Class A oxidoreductases transfer the atom from above; class B enzymes transfer it from below. Since the C4 carbon that accepts the hydrogen is prochiral, this can be exploited in enzyme kinetics to give information about the enzyme's mechanism. This is done by mixing an enzyme with a substrate that has deuterium atoms substituted for the hydrogens, so the enzyme will reduce NAD by transferring deuterium rather than hydrogen. In this case, an enzyme can produce one of two stereoisomers of NADH.
Despite the similarity in how proteins bind the two coenzymes, enzymes almost always show a high level of specificity for either NAD or NADP. This specificity reflects the distinct metabolic roles of the respective coenzymes, and is the result of distinct sets of amino acid residues in the two types of coenzyme-binding pocket. For instance, in the active site of NADP-dependent enzymes, an ionic bond is formed between a basic amino acid side-chain and the acidic phosphate group of NADP. On the converse, in NAD-dependent enzymes the charge in this pocket is reversed, preventing NADP from binding. However, there are a few exceptions to this general rule, and enzymes such as aldose reductase, glucose-6-phosphate dehydrogenase, and methylenetetrahydrofolate reductase can use both coenzymes in some species.
Role in redox metabolism
The redox reactions catalyzed by oxidoreductases are vital in all parts of metabolism, but one particularly important function of these reactions is to enable nutrients to unlock the energy stored in the relatively weak double bond of oxygen.
[ ] Here, reduced compounds such as glucose and fatty acids are oxidized, thereby releasing the chemical energy of O2. In this process, NAD is reduced to NADH, as part of beta oxidation, glycolysis, and the citric acid cycle. In eukaryotes the electrons carried by the NADH that is produced in the cytoplasm are transferred into the mitochondrion (to reduce mitochondrial NAD) by mitochondrial shuttles, such as the malate-aspartate shuttle. The mitochondrial NADH is then oxidized in turn by the electron transport chain, which pumps protons across a membrane and generates ATP through oxidative phosphorylation. These shuttle systems also have the same transport function in chloroplasts.
Since both the oxidized and reduced forms of nicotinamide adenine dinucleotide are used in these linked sets of reactions, the cell maintains significant concentrations of both NAD and NADH, with the high NAD/NADH ratio allowing this coenzyme to act as both an oxidizing and a reducing agent. In contrast, the main function of NADPH is as a reducing agent in anabolism, with this coenzyme being involved in pathways such as fatty acid synthesis and photosynthesis. Since NADPH is needed to drive redox reactions as a strong reducing agent, the NADP/NADPH ratio is kept very low. [
Although it is important in catabolism, NADH is also used in anabolic reactions, such as gluconeogenesis. This need for NADH in anabolism poses a problem for prokaryotes growing on nutrients that release only a small amount of energy. For example, nitrifying bacteria such as ''Nitrobacter'' oxidize nitrite to nitrate, which releases sufficient energy to pump protons and generate ATP, but not enough to produce NADH directly. As NADH is still needed for anabolic reactions, these bacteria use a nitrite oxidoreductase to produce enough proton-motive force to run part of the electron transport chain in reverse, generating NADH.
The coenzyme NAD is also consumed in ADP-ribose transfer reactions. For example, enzymes called ADP-ribosyltransferases add the ADP-ribose moiety of this molecule to proteins, in a posttranslational modification called ADP-ribosylation. ADP-ribosylation involves either the addition of a single ADP-ribose moiety, in ''mono-ADP-ribosylation'', or the transferral of ADP-ribose to proteins in long branched chains, which is called ''poly(ADP-ribosyl)ation''.
Mono-ADP-ribosylation was first identified as the mechanism of a group of bacterial toxins, notably cholera toxin, but it is also involved in normal cell signaling. Poly(ADP-ribosyl)ation is carried out by the poly(ADP-ribose) polymerases. The poly(ADP-ribose) structure is involved in the regulation of several cellular events and is most important in the cell nucleus, in processes such as DNA repair and telomere maintenance. [ In addition to these functions within the cell, a group of extracellular ADP-ribosyltransferases has recently been discovered, but their functions remain obscure.
NAD may also be added onto cellular RNA as a 5'-terminal modification.
Another function of this coenzyme in cell signaling is as a precursor of cyclic ADP-ribose, which is produced from NAD by ADP-ribosyl cyclases, as part of a second messenger system. This molecule acts in calcium signaling by releasing calcium from intracellular stores. It does this by binding to and opening a class of calcium channels called ryanodine receptors, which are located in the membranes of organelles, such as the endoplasmic reticulum.
NAD is also consumed by sirtuins, which are NAD-dependent deacetylases, such as Sir2. These enzymes act by transferring an acetyl group from their substrate protein to the ADP-ribose moiety of NAD; this cleaves the coenzyme and releases nicotinamide and O-acetyl-ADP-ribose. The sirtuins mainly seem to be involved in regulating transcription through deacetylating histones and altering nucleosome structure. However, non-histone proteins can be deacetylated by sirtuins as well. These activities of sirtuins are particularly interesting because of their importance in the regulation of aging.
Other NAD-dependent enzymes include bacterial DNA ligases, which join two DNA ends by using NAD as a substrate to donate an adenosine monophosphate (AMP) moiety to the 5' phosphate of one DNA end. This intermediate is then attacked by the 3' hydroxyl group of the other DNA end, forming a new phosphodiester bond. This contrasts with eukaryotic DNA ligases, which use ATP to form the DNA-AMP intermediate.
Li et al. have found that NAD directly regulates protein-protein interactions.] They also show that one of the causes of age-related decline in DNA repair may be increased binding of the protein DBC1 (Deleted in Breast Cancer 1) to PARP1 (polyDP–ribosepolymerase 1) as NAD levels decline during aging. Thus, the modulation of NAD may protect against cancer, radiation, and aging.
Extracellular actions of NAD+
In recent years, NAD+ has also been recognized as an extracellular signaling molecule involved in cell-to-cell communication.
NAD+ is released from neurons in blood vessels, [ urinary bladder,] large intestine, from neurosecretory cells, and from brain synaptosomes, and is proposed to be a novel neurotransmitter that transmits information from nerves to effector cells in smooth muscle organs. [ In plants, the extracellular nicotinamide adenine dinucleotide induces resistance to pathogen infection and the first extracellular NAD receptor has been identified.] Further studies are needed to determine the underlying mechanisms of its extracellular actions and their importance for human health and life processes in other organisms.
The enzymes that make and use NAD and NADH are important in both pharmacology and the research into future treatments for disease. Drug design and drug development exploits NAD in three ways: as a direct target of drugs, by designing enzyme inhibitors or activators based on its structure that change the activity of NAD-dependent enzymes, and by trying to inhibit NAD biosynthesis.
Because cancer cells utilize increased glycolysis, and because NAD enhances glycolysis, nicotinamide phosphoribosyltransferase (NAD salvage pathway) is often amplified in cancer cells.
It has been studied for its potential use in the therapy of neurodegenerative diseases such as Alzheimer's and Parkinson's disease. [ A placebo-controlled clinical trial of NADH (which excluded NADH precursors) in people with Parkinson's failed to show any effect.
NAD is also a direct target of the drug isoniazid, which is used in the treatment of tuberculosis, an infection caused by ''Mycobacterium tuberculosis''. Isoniazid is a prodrug and once it has entered the bacteria, it is activated by a peroxidase enzyme, which oxidizes the compound into a free radical form. This radical then reacts with NADH, to produce adducts that are very potent inhibitors of the enzymes enoyl-acyl carrier protein reductase, and dihydrofolate reductase.
Since a large number of oxidoreductases use NAD and NADH as substrates, and bind them using a highly conserved structural motif, the idea that inhibitors based on NAD could be specific to one enzyme is surprising.] However, this can be possible: for example, inhibitors based on the compounds mycophenolic acid and tiazofurin inhibit IMP dehydrogenase at the NAD binding site. Because of the importance of this enzyme in purine metabolism, these compounds may be useful as anti-cancer, anti-viral, or immunosuppressive drugs. Other drugs are not enzyme inhibitors, but instead activate enzymes involved in NAD metabolism. Sirtuins are a particularly interesting target for such drugs, since activation of these NAD-dependent deacetylases extends lifespan in some animal models. Compounds such as resveratrol increase the activity of these enzymes, which may be important in their ability to delay aging in both vertebrate, and invertebrate model organisms. In one experiment, mice given NAD for one week had improved nuclear-mitochrondrial communication.
Because of the differences in the metabolic pathways of NAD biosynthesis between organisms, such as between bacteria and humans, this area of metabolism is a promising area for the development of new antibiotics. For example, the enzyme nicotinamidase, which converts nicotinamide to nicotinic acid, is a target for drug design, as this enzyme is absent in humans but present in yeast and bacteria. [
In bacteriology, NAD, sometimes referred to factor V, is used a supplement to culture media for some fastidious bacteria.
The coenzyme NAD was first discovered by the British biochemists Arthur Harden and William John Young in 1906. They noticed that adding boiled and filtered yeast extract greatly accelerated alcoholic fermentation in unboiled yeast extracts. They called the unidentified factor responsible for this effect a ''coferment''. Through a long and difficult purification from yeast extracts, this heat-stable factor was identified as a nucleotide sugar phosphate by Hans von Euler-Chelpin. In 1936, the German scientist Otto Heinrich Warburg showed the function of the nucleotide coenzyme in hydride transfer and identified the nicotinamide portion as the site of redox reactions.
Vitamin precursors of NAD were first identified in 1938, when Conrad Elvehjem showed that liver has an "anti-black tongue" activity in the form of nicotinamide. Then, in 1939, he provided the first strong evidence that niacin is used to synthesize NAD. In the early 1940s, Arthur Kornberg was the first to detect an enzyme in the biosynthetic pathway. In 1949, the American biochemists Morris Friedkin and Albert L. Lehninger proved that NADH linked metabolic pathways such as the citric acid cycle with the synthesis of ATP in oxidative phosphorylation. In 1958, Jack Preiss and Philip Handler discovered the intermediates and enzymes involved in the biosynthesis of NAD; salvage synthesis from nicotinic acid is termed the Preiss-Handler pathway. In 2004, Charles Brenner and co-workers uncovered the nicotinamide riboside kinase pathway to NAD.
The non-redox roles of NAD(P) were discovered later. [ The first to be identified was the use of NAD as the ADP-ribose donor in ADP-ribosylation reactions, observed in the early 1960s. Studies in the 1980s and 1990s revealed the activities of NAD and NADP metabolites in cell signaling – such as the action of cyclic ADP-ribose, which was discovered in 1987.
The metabolism of NAD remained an area of intense research into the 21st century, with interest heightened after the discovery of the NAD-dependent protein deacetylases called sirtuins in 2000, by Shin-ichiro Imai and coworkers in the laboratory of Leonard P. Guarente.] In 2009 Imai proposed the "NAD World" hypothesis that key regulators of aging and longevity in mammals are sirtuin 1 and the primary NAD synthesizing enzyme nicotinamide phosphoribosyltransferase (NAMPT). In 2016 Imai expanded his hypothesis to "NAD World 2.0" which postulates that extracellular NAMPT from adipose tissue maintains NAD in the hypothalamus (the control center) in conjunction with myokines from skeletal muscle cells.
*List of oxidoreductases
*, A history of early enzymology.
*, a textbook from the 19th century.
NAD bound to proteins
in the Protein Data Bank
β-Nicotinamide adenine dinucleotide (NAD, oxidized)
Chemical data sheet from Sigma-Aldrich
NAD synthesis pathway
at the MetaCyc database
List of oxidoreductases
at the SWISS-PROT database